Compare LCII & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCII | HRMY |
|---|---|---|
| Founded | 1956 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 1994 | 2020 |
| Metric | LCII | HRMY |
|---|---|---|
| Price | $106.88 | $39.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $130.86 | $44.11 |
| AVG Volume (30 Days) | 304.0K | ★ 900.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | ★ 35.18 | 7.97 |
| EPS | ★ 5.29 | 1.84 |
| Revenue | ★ $4,122,017,000.00 | $868,453,000.00 |
| Revenue This Year | $5.56 | $19.75 |
| Revenue Next Year | $4.25 | $12.88 |
| P/E Ratio | ★ $20.29 | $21.48 |
| Revenue Growth | 10.18 | ★ 21.51 |
| 52 Week Low | $84.33 | $25.52 |
| 52 Week High | $159.66 | $40.87 |
| Indicator | LCII | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 64.94 |
| Support Level | $102.95 | $34.87 |
| Resistance Level | $110.19 | $40.87 |
| Average True Range (ATR) | 3.83 | 1.29 |
| MACD | 0.02 | 0.32 |
| Stochastic Oscillator | 64.00 | 90.92 |
LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries, including buses and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments: the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold to manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.